Guidance

Update on HIV, Cardiovascular Risk and Statin use

Summary

People living with HIV (PLWH) are at higher risk of atherosclerotic cardiovascular disease. Q-risk 3 does not adjust for HIV. A recent study has shown that there is a significant reduction of major adverse cardiovascular events in participants assigned to a statin.

 

Recommendations

All 40 yr + PLWH offered a statin.

Patients with a Q-risk 5%+ should be prioritised

Atorvastain 20mg first choice at present

If unable to tolerate to try other alternative lipid lowering agent

 

Action

In HIV clinic we are discussing CVD, Q-Risk and statin use with all patients 40 years+

We will communicate the Q-risk score and request consideration from yourselves regarding statin prescription and monitoring in all PLWH 40yrs + with a Q-risk 5%+.

We will ask the PLWH who wish to consider a statin to approach you to discuss this further.

First Published
26 July 2024
Updated On
26 July 2024
Due to be Reviewed
26 July 2025
Not signed in.

Please Login or Register an account to access the ability to favourite this.
Share this article

You might also find this useful...

Why a Current GP Partnership Agreement Matters
Why a Current GP Partnership Agreement Matters
17 February 2025
In today’s fast-evolving healthcare landscape, General Practitioner (GP) partnerships operate in an environment full of regulatory, financial, and operational challenges. A robust and current partnership agreement is not just a…
Cont. Reading